Skip to main content

Artivion, Inc.

AORT
Exchange
NYSE
Industry
Surgical & Medical Instruments & Apparatus
SEC CIK
0000784199

In the last 90 days, Artivion, Inc. insiders filed 0 open-market purchases and 6 sales; 206 institutions reported holding it in 13F filings for Q2 2026, worth $1.03B in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Artivion, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
6 filings
4 insiders, $2.60M in total
Insiders trading
4
Net value
−$2.60M
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Artivion, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Artivion, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Green Andrew MSVP, Regulatory and Quality40,160Sep 11, 20264
Mackin James PPresident & CEO877,275Aug 20, 20268
Berry Lance AEVP, COO, CFO & Treasurer210,112Aug 17, 20264
Holloway Jean FSVP, General Counsel184,118Aug 12, 20268
Semedo Anthony B.Director6,325IndirectJun 4, 20262
Ackerman Thomas FDirector157,472May 20, 20261
Bullock JamesDirector76,223May 20, 20261
Bevevino Daniel JDirector157,637May 20, 20261
Burbank Jeffrey HDirector61,372May 20, 20261
Salveson Jon WDirector137,416May 20, 20261
Borgstrom Marna PDirector56,664May 20, 20261
Hoff Elizabeth ADirector34,765May 20, 20262
Horton AmyVP, Chief Accounting Officer139,088Mar 4, 20268
Davis John EChief Commercial Officer230,794Mar 4, 20267
Stanton Marshall S.SVP, Clinical & MD Affair60,097Mar 4, 20267
Getz Matthew AVP, Human Resources34,116Aug 19, 20240
Maney Rochelle L.VP, Quality44,518Mar 14, 20240
Tyrs FlorianVP, Global Operations21,558Feb 29, 20240
Thomson Robert CVP Research & Development13,291Feb 26, 20240
Maier Dennis BSVP, Operations34,724Jun 8, 20230
Lee David AshleyExecutive VP, COO & CFO347,217Mar 3, 20230
Barthold Franz PeterVP, Research & Development32,516Nov 10, 20220
Morgan HarveyDirector46,342IndirectAug 31, 20210
McCall Ronald DDirector121,768Aug 26, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Mar 14, 2024 (view filing)Mar 59 daysMackin James PPresident & CEOSSale−14.0K$18.72−$262.0K−1.9%706.0K afterAmended
Mar 14, 2024 (view filing)Mar 59 daysDavis John EChief Commercial OfficerSSale−2.02K$18.72−$37.9K−1.2%165.7K afterAmended
Mar 14, 2024 (view filing)Mar 59 daysGetz Matthew AVP, Human ResourcesSSale−1.16K$18.72−$21.7K−2.3%48.5K afterAmended
Mar 14, 2024 (view filing)Mar 59 daysGreen Andrew MVP RegulatorySSale−1.16K$18.72−$21.7K−2.4%46.6K afterAmended
Mar 14, 2024 (view filing)Mar 59 daysHolloway Jean FSVP, General CounselSSale−2.38K$18.72−$44.6K−1.4%169.7K afterAmended
Mar 14, 2024 (view filing)Feb 2716 daysMackin James PPresident & CEOSSale−4.84K$19.83−$95.9K−0.7%691.4K afterAmended
Mar 14, 2024 (view filing)Mar 59 daysManey Rochelle L.VP, QualitySSale−1.16K$18.72−$21.7K−2.4%46.6K afterAmended
Mar 14, 2024 (view filing)Feb 2716 daysGetz Matthew AVP, Human ResourcesSSale−325$19.83−$6.44K−0.7%46.1K afterAmended
Mar 14, 2024 (view filing)Feb 2617 daysGetz Matthew AVP, Human ResourcesSSale−2.28K$20.27−$46.2K−4.7%46.4K afterAmended2 lots
Mar 14, 2024 (view filing)Mar 113 daysStanton Marshall S.SVP, Clinical & MD AffairSSale−1.51K$18.72−$28.2K−1.7%85.5K afterAmended
Mar 14, 2024 (view filing)Mar 59 daysHorton AmyVP, Chief Accounting OfficerSSale−1.15K$18.72−$21.6K−0.8%140.0K afterAmended
Mar 14, 2024 (view filing)Feb 2716 daysHolloway Jean FSVP, General CounselSSale−485$19.83−$9.62K−0.3%166.4K afterAmended
Mar 14, 2024 (view filing)Feb 2617 daysMackin James PPresident & CEOSSale−30.8K$20.27−$625.0K−4.2%696.3K afterAmended2 lots
Mar 14, 2024 (view filing)Feb 2716 daysDavis John EChief Commercial OfficerSSale−584$19.83−$11.6K−0.4%162.0K afterAmended
Mar 14, 2024 (view filing)Feb 2716 daysHorton AmyVP, Chief Accounting OfficerSSale−325$19.83−$6.44K−0.2%137.6K afterAmended
Mar 14, 2024 (view filing)Feb 2716 daysGreen Andrew MVP RegulatorySSale−421$19.83−$8.35K−0.9%44.2K afterAmended
Mar 14, 2024 (view filing)Feb 2716 daysManey Rochelle L.VP, QualitySSale−370$19.83−$7.34K−0.8%44.1K afterAmended
Mar 14, 2024 (view filing)Feb 2716 daysStanton Marshall S.SVP, Clinical & MD AffairSSale−465$19.83−$9.22K−0.6%81.3K afterAmended
Mar 14, 2024 (view filing)Feb 2617 daysDavis John EChief Commercial OfficerSSale−3.46K$20.27−$70.2K−2.1%162.6K afterAmended2 lots
Mar 14, 2024 (view filing)Feb 2617 daysGreen Andrew MVP RegulatorySSale−2.37K$20.27−$48.0K−5.0%44.6K afterAmended2 lots
Mar 14, 2024 (view filing)Feb 2617 daysHolloway Jean FSVP, General CounselSSale−2.84K$20.27−$57.5K−1.7%166.9K afterAmended2 lots
Mar 14, 2024 (view filing)Feb 2617 daysManey Rochelle L.VP, QualitySSale−2.28K$20.27−$46.3K−4.9%44.5K afterAmended2 lots
Mar 14, 2024 (view filing)Feb 2617 daysStanton Marshall S.SVP, Clinical & MD AffairSSale−3.01K$20.27−$61.0K−3.5%81.7K afterAmended2 lots
Mar 14, 2024 (view filing)Feb 2617 daysHorton AmyVP, Chief Accounting OfficerSSale−2.13K$20.27−$43.3K−1.5%137.9K afterAmended2 lots
Mar 14, 2024 (view filing)Mar 122 daysGetz Matthew AVP, Human ResourcesSSale−5.00K$19.94−$99.7K−10.3%43.5K after
Mar 15, 2024 (view filing)Mar 141 dayGreen Andrew MVP RegulatorySSale−3.99K$20.00−$79.9K−8.6%42.6K after10b5-1
Mar 18, 2024 (view filing)Mar 153 daysGreen Andrew MVP RegulatorySSale−1.46K$20.00−$29.2K−3.4%41.1K after10b5-1
Mar 21, 2024 (view filing)Mar 201 dayStanton Marshall S.SVP, Clinical & MD AffairSSale−2.18K$20.39−$44.5K−2.6%83.3K after
May 10, 2024 (view filing)May 91 dayHolloway Jean FSVP, General CounselSSale−979$23.79−$23.3K−0.6%168.7K after
May 13, 2024 (view filing)May 103 daysHolloway Jean FSVP, General CounselSSale−1.25K$23.42−$29.3K−0.7%167.5K after
Aug 15, 2024 (view filing)Aug 132 daysSemedo Anthony B.DirectorSSale−9.71K$24.99−$242.6K−22.1%34.2K after
Aug 16, 2024 (view filing)Aug 151 dayHolloway Jean FSVP, General CounselSSale−2.38K$25.76−$61.4K−1.4%165.1K after
Aug 19, 2024 (view filing)Aug 163 daysGetz Matthew AVP, Human ResourcesSSale−9.42K$25.31−$238.4K−21.6%34.1K after2 lots
Aug 27, 2024 (view filing)Aug 261 dayHolloway Jean FSVP, General CounselSSale−3.17K$26.55−$84.1K−1.9%161.9K after
Oct 2, 2024 (view filing)Oct 11 dayHorton AmyVP, Chief Accounting OfficerSSale−12.4K$26.18−$325.4K−8.2%140.0K after10b5-1
Dec 4, 2024 (view filing)Dec 4Same dayGreen Andrew MVP RegulatorySSale−7.62K$30.00−$228.5K−18.5%33.5K after10b5-1
Dec 10, 2024 (view filing)Dec 64 daysHorton AmyVP, Chief Accounting OfficerSSale−4.42K$29.05−$128.5K−3.2%135.6K afterAmended
Dec 12, 2024 (view filing)Dec 111 dayHolloway Jean FSVP, General CounselSSale−8.07K$30.13−$243.1K−5.0%153.9K after2 lots
Feb 26, 2025 (view filing)Feb 242 daysStanton Marshall S.SVP, Clinical & MD AffairSSale−4.69K$27.31−$128.0K−5.5%79.8K after4 lots
Feb 26, 2025 (view filing)Feb 242 daysBerry Lance AExecutive VP, CFOSSale−3.26K$27.31−$89.0K−4.1%75.8K after
Feb 26, 2025 (view filing)Feb 242 daysDavis John EChief Commercial OfficerSSale−6.46K$27.31−$176.3K−3.9%160.6K after4 lots
Feb 26, 2025 (view filing)Feb 242 daysHolloway Jean FSVP, General CounselSSale−5.33K$27.31−$145.7K−3.4%149.8K after4 lots
Feb 26, 2025 (view filing)Feb 242 daysMackin James PPresident & CEOSSale−42.2K$27.31−$1.15M−6.0%663.9K after4 lots
Feb 26, 2025 (view filing)Feb 242 daysHorton AmyVP, Chief Accounting OfficerSSale−3.32K$27.31−$90.8K−2.5%131.1K after4 lots
Mar 5, 2025 (view filing)Mar 5Same daySemedo Anthony B.DirectorPPurchase+1.50K$25.33+$38.0K+4.4%35.7K after
Mar 5, 2025 (view filing)Mar 5Same daySemedo Anthony B.DirectorPPurchase+600$25.25+$15.2KNew position600 after
Mar 6, 2025 (view filing)Mar 51 dayHolloway Jean FSVP, General CounselSSale−472$25.29−$11.9K−0.3%172.7K after
Mar 10, 2025 (view filing)Mar 64 daysHolloway Jean FSVP, General CounselSSale−2.12K$24.80−$52.7K−1.1%196.1K after
Mar 10, 2025 (view filing)Mar 64 daysStanton Marshall S.SVP, Clinical & MD AffairSSale−1.60K$24.80−$39.8K−1.4%115.9K after
Mar 10, 2025 (view filing)Mar 64 daysDavis John EChief Commercial OfficerSSale−2.62K$24.80−$64.9K−1.2%208.0K after